The treatment of severe aplastic anemia with hematopoietic stem cell transplantation
10.3760/cma.j.issn.1008-6315.2010.06.005
- VernacularTitle:造血干细胞移植治疗重型再生障碍性贫血
- Author:
Zhijuan YAO
;
Jun WANG
;
Wenli ZHANG
;
Hongyu ZHANG
;
Lihua SUN
;
Qingxiang MENG
;
Nailan GUO
- Publication Type:Journal Article
- Keywords:
Aplastic anemia;
Allogeneic hematopoietic stem cell transplantation;
Graft versus host disease;
Graft rejection
- From:
Clinical Medicine of China
2010;26(6):575-578
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effects of allogeneic hematopoietic stem cell transplantat (allo-HSCT) for severe aplastic anemia (SAA). Methods Four patients of SAA underwent allo-HSCT at the bonemarrow transplant unit in our hospital from March 2003 to May 2009. Stem cell source was an HLA (human leukocyte antigen) matched related donor (MRD) in 3, HLA 1 (B) mismatched related donor in 1 patient A retrospective analysis was performed on interval from diagnosis to transplant,HSCT manners,conditioning regimens, hematopoiesis reconstitution, effectiveness and complication. Results The interval from diagnosis to transplant was 70 (19 - 180) days. Three patients (MRD) underwent BM + PBSCT, one was undergone BM + PBSC + CBSCT. Conditioning regimens of all patients were CY/ATG. Hematopoiesis reconstitution was achieved in 4 patients (100%). The median time of neutrophils which reached 0. 5 x 109/L and platelets reached 20 × 109/L were 14. 5 (9-28) and 16(9 -28) days. Two cases developed grade Ⅰ acute graft-versus-host diseaes (aGVHD), chronic local GVHD occurred in one patient. Four patients are alive with a median time of 40. 6(2 -63) months at the end of the following-up. Conclusions Allo-HSCT are an efficient and safe therapy for the patient with SAA,not only for patients with HLA matched related donor,but also for those only HLA mismatched related donor available.
